Life Sciences News | BioTuesdays by Kilmer Lucas IR

Markets

RJ ups Eupraxia to strong buy ahead of Phase 2 OA data

Raymond James upgraded Eupraxia Pharmaceuticals (TSX:EPRX) to “strong buy” from “outperform” and maintained its price target of $11 (Canadian). The stock was quoted at $6.99, up 15 cents at midday on May 18. Pointing to...

May 18, 2023

Markets

BTIG starts Coya Therapeutics at buy; PT $15

BTIG launched coverage of Coya Therapeutics (NASDAQ:COYA) with a “buy” rating and a $15 price target. The stock closed at $5.76 on May 17. Analyst Thomas Shrader, Ph.D., writes that his price target is based on “our...

May 18, 2023

Developments

EyePoint to sell YUTIQ to Alimera Sciences for $82.5-million

EyePoint Pharmaceuticals (NASDAQ:EYPT) entered into a definitive agreement for the sale of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18mg to Alimera Sciences (NASDAQ:ALIM). Under the accord, EyePoint...

May 18, 2023

Developments

FDA eases partial clinical hold on Avidity dosing

The FDA eased a partial clinical hold on AOC 1001, allowing Avidity Biosciences (NASDA:RNA) to double the number of participants in the MARINA open-label extension (MARINA-OLE) study receiving 4 mg/kg of AOC 1001. The...

May 17, 2023

Developments

IntelGenx receives amended Health Canada license for third-party testing

IntelGenx (TSX:IGX; OTCQB:IGXT) received an amended Drug Establishment License (DEL) from Health Canada, allowing the company to conduct third-party testing. Analytical testing of finished products and intermediates is...

May 17, 2023

Developments

Dermavant posts positive results in second Phase 3 for atopic dermatitis

Dermavant Sciences, a subsidiary of Roivant Sciences (NASDAQ:ROIV), reported positive results from ADORING 1, the second of two double-blind, randomized, vehicle-controlled Phase 3 studies to evaluate the efficacy and...

May 16, 2023

Developments

Chinook, Ionis partner to develop antisense therapy for CKD

Chinook Therapies (NASDAQ:KDNY) entered into a collaboration agreement with Ionis Pharmaceuticals for the discovery, development and commercialization of an antisense oligonucleotide (ASO) therapy for a rare, severe...

May 16, 2023

Executive Moves

Conavi Medical names CV device veteran Brian Chambless as CCO

Conavi Medical appointed accomplished cardiovascular medical device industry veteran, Brian Chambless, to the newly created position of chief commercial officer (CCO). In an executive management career spanning more...

May 15, 2023

Developments

Oramed partner in China moving oral insulin to regulatory approval

Oramed Pharmaceuticals’ (NASDAQ, TASE:ORMP) strategic partner, Hefei Tianhui Biotechnology, successfully completed its Phase 3 trials of oral insulin in Type 2 diabetes patients in China under a differentiated study...

May 15, 2023

Markets

Cantor and Brookline change Hepion PTs to $28 and $74 post-split

Cantor Fitzgerald raised its price target for Hepion Pharmaceuticals (NASDAQ:HEPA) to $28 after a one-for-20 reverse stock split on May 10, and maintained an “overweight” rating. The stock closed at $6.81 on Friday. “We...

May 15, 2023

Developments

POINT invests in alpha-emitting Isotope maker

POINT Biopharma Global (NASDAQ:PNT) and IONETIX are collaborating to create Ionetix Alpha Corp., a new subsidiary of IONETIX, to focus on near-term, commercial-scale production of GMP-grade therapeutic isotopes, such as...

May 15, 2023

Developments

Last patient treated in Bellerophon Phase 3 trial in fibrotic lung disease

The last patient has completed blinded treatment in Bellerophon Therapeutics’ (NASDAQ:BLPH) Phase 3 REBUILD study of INOpulse, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic...

May 11, 2023

RJ ups Eupraxia to strong buy ahead of Phase 2 OA data

BTIG starts Coya Therapeutics at buy; PT $15

EyePoint to sell YUTIQ to Alimera Sciences for $82.5-million

FDA eases partial clinical hold on Avidity dosing

IntelGenx receives amended Health Canada license for third-party testing

Dermavant posts positive results in second Phase 3 for atopic dermatitis

Chinook, Ionis partner to develop antisense therapy for CKD

Conavi Medical names CV device veteran Brian Chambless as CCO

Oramed partner in China moving oral insulin to regulatory approval

Cantor and Brookline change Hepion PTs to $28 and $74 post-split

POINT invests in alpha-emitting Isotope maker

Last patient treated in Bellerophon Phase 3 trial in fibrotic lung disease

General

More